KZIA Stock — Kazia Therapeutics Limited: Cash, EV, Pipeline

Share price

$10.39

Market cap

$161.6M

Cash

$2.8M

Enterprise value

$158.8M

Balance sheet

Cash	$2.8M
Debt	$0.0M
Net cash	$2.8M
Enterprise value	$158.8M
Basic shares	15.6M shares
Fully diluted shares	9.0M shares
Fully diluted market cap	$93.7M
Cash per share	$0.18

Cash figures as of 2025-06-30. Database snapshot: 2026-09-21.

Price history

Loading KZIA daily closes…

Loading price history…

Pipeline assets

Paxalisib

Stage not disclosed · Active Modality: small molecule

Aliases GDC-0084

Target PI3K/Akt/mTOR

Status note Lead program; small molecule inhibitor of the PI3K/Akt/mTOR pathway in clinical trials. Filing excerpts do not disclose the indication or trial phase for this filing period.

EVT801

Stage not disclosed · Active Modality: small molecule

Target VEGFR3

Status note Small molecule selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3) in clinical trials. Filing excerpts do not disclose the indication or trial phase for this filing period.

Per-asset detail extracted from the 20-F filed 2025-11-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	396,201	+396,201	0.91%	2026-08-14
ADAR1 Capital Management	61,550	+61,550	0.04%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

KZIA — Kazia Therapeutics Limited

Balance sheet

Price history

Pipeline assets

Institutional holders